Payment overview · 2025
General Payments
$221.26
12 reported records · 5 companies
Healthcare provider profile · identity verified
Lori Ann England-Wright, M.D.
Allopathic & Osteopathic Physicians|General Practice · BOWLING GREEN, KY · NPI 1477536829
Verified facts
What the public records show
CMS Open Payments records show Lori Ann England-Wright, M.D. received $221.26 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 40.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.52 | 40.9% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $68.33 | 30.9% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.68 | 12.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.00 | 9.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.73 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $221.26 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $90.52 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $68.33 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.68 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 508 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 339 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 290 | 56 |
| Lisinopril | Lisinopril | 261 | 60 |
| Jardiance | Empagliflozin | 209 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 49 |
| Omeprazole | Omeprazole | 176 | 37 |
| Metformin Hcl | Metformin Hcl | 172 | 44 |
| Gabapentin | Gabapentin | 165 | 35 |
| Ezetimibe | Ezetimibe | 154 | 30 |
| Ozempic | Semaglutide | 148 | 26 |
| Furosemide | Furosemide | 144 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 139 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 33 |
| Alendronate Sodium | Alendronate Sodium | 132 | 28 |
| Sertraline Hcl | Sertraline Hcl | 125 | 32 |
| Glipizide | Glipizide | 122 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 27 |
| Tramadol Hcl | Tramadol Hcl | 107 | 22 |
| Buspirone Hcl | Buspirone Hcl | 105 | 24 |
| Metformin Hcl Er | Metformin Hcl | 101 | 20 |
| Losartan Potassium | Losartan Potassium | 97 | 28 |
| Potassium Chloride | Potassium Chloride | 90 | 24 |
| Januvia | Sitagliptin Phosphate | 86 | 17 |
| Meloxicam | Meloxicam | 85 | 22 |
| Famotidine | Famotidine | 83 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 13 |
| Trazodone Hcl | Trazodone Hcl | 73 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 17 |
| Ibuprofen | Ibuprofen | 71 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 26 |
| Tradjenta | Linagliptin | 67 | 12 |
| Farxiga | Dapagliflozin Propanediol | 64 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 15 |
| Carvedilol | Carvedilol | 62 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 56 | 15 |
| Spironolactone | Spironolactone | 56 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 54 | 11 |
| Montelukast Sodium | Montelukast Sodium | 51 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 15 |
| Benazepril Hcl | Benazepril Hcl | 50 | 12 |
| Glimepiride | Glimepiride | 49 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | suppressed |
| Trulicity | Dulaglutide | 47 | suppressed |
| Fluconazole | Fluconazole | 45 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | suppressed |
| Eliquis | Apixaban | 42 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Allopurinol | Allopurinol | 38 | 11 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | 12 |
| Vraylar | Cariprazine Hcl | 30 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 15 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Simvastatin | Simvastatin | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 16 |
| Naproxen | Naproxen | 20 | suppressed |
| Nystatin | Nystatin | 20 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Alyacen | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Cozaar | Losartan Potassium | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $221.26 · 12 records | ABBVIE INC. | AIRSUPRA, Dexcom G6 Transmitter, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error